Table 2.

Summary of drug regimen

Trial name	First dose	Second dose
		Timing	Indication
RECOVERY [5]	800 mg if weight > 90 kg 600 mg if weight 65–90 kg 400 mg if weight 40–65 kg 8 mg/kg if weight ≤ 40 kg	After 12–24 h	If no improvement according to the attending clinician. 29% received a second dose
REMAP-CAP [6]	8 mg/kg, maximum of 800 mg	After 12–24 h	If no improvement according to the attending clinician. 29% received a second dose
CORIMUNO-TOCI [7]	8 mg/kg	Day 3	If oxygen requirement did not decrease by 50% 47% received a second dose
EMPACTA [8]	8 mg/kg, maximum of 800 mg	After 8–24 h	if no improvement or worsening of clinical state on a 7-point ordinal scale* 27.2% patients received a second dose
COVINTOC [9]	6 mg/kg maximum of 480 mg	Within 12 h to 7 days	If no improvement or worsening clinical state
TOCIBRAS [10]	8 mg/kg, maximum of 800 mg	NA
COVACTA [11]	8 mg/kg, maximum of 800 mg	After 8–24 h	If no improvement or worsening clinical state on a 7-point ordinal scale* 22.1% patients received a second dose
BACC-Bay [12]	8 mg/kg, maximum of 800 mg	NA
RCT-TCZ-COVID-19 [13]	8 mg/kg, maximum of 800 mg	After 12 h	To all patients in TCZ group

ECMO extra-corporeal membrane oxygenation, ICU intensive care unit, NA not applicable, TCZ tocilizumab

*7-point ordinal scale: 1: Discharged (or “ready for discharge” as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or ≤ 2L supplemental oxygen); 2: Non-ICU hospital ward (or “ready for hospital ward”) not requiring supplemental oxygen; 3: Non-ICU hospital ward (or “ready for hospital ward”) requiring supplemental oxygen; 4: ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen; 5: ICU, requiring intubation and mechanical ventilation; 6: ICU, requiring ECMO or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy); 7: Death